Onika T. Murray, Ph.D.
|2012||Molecular and Cellular Pharmacology||Stony Brook University, Stony Brook, NY, United States|
Area:Pharmacology, Molecular Biology
Mean distance: (not calculated yet)
ParentsSign in to add mentor
ChildrenSign in to add trainee
CollaboratorsSign in to add collaborator
BETA: Related publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
|Murray OT, Wong CC, Vrankova K, et al. (2014) Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. International Journal of Oncology. 44: 521-9|
|Xie G, Nie T, Mackenzie GG, et al. (2012) The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine. British Journal of Pharmacology. 165: 2152-66|
|Murray OT, Vrankova K, Johnson F, et al. (2012) Abstract 4431: NFATc1 silencing increases sensitivity of pancreatic cancer cells to phosphosulindac Cancer Research. 72: 4431-4431|
|Zhao W, Mackenzie GG, Murray OT, et al. (2009) Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. Carcinogenesis. 30: 512-9|